Delta-8-THC: A public health perspective with Eric Leas, PhD

SummaryIn this conversation, Dr. Igor Grant and Dr. Eric Leas delve into the complexities surrounding Delta-8-THC, exploring its differences from Delta-9-THC, consumer demand, regulatory challenges, and safety concerns. They discuss the implications of state regulations on the market, the need for compliance in cannabis research, and the future of Delta-8-THC regulation. The conversation also touches on the broader landscape of cannabinoids and psychoactive substances, highlighting the ongoing evolution of cannabis regulation and public health considerations.TakeawaysDelta-8-THC is structurally similar to Delta-9-THC but less psychotropic effect.Consumer demand for Delta-8 is driven by its legal status as a hemp product in states without medical or recreational cannabis use regulations.Regulatory challenges exist due to the lack of standardized safety measures.States with legal cannabis markets are concerned about competition from Delta-8 products.Research on Delta-8 is limited, necessitating further studies on its effects.The market for Delta-8 is largely unregulated, raising safety concerns.There is a growing interest in other cannabinoids and psychoactive substances.Compliance checks in cannabis retail are complicated by federal laws.The patchwork of state regulations creates confusion for consumers and manufacturers.Chapters: 00:00 Introduction to Delta-8 THC02:51 Understanding Delta-8 THC: Differences and Similarities05:15 Consumer Demand: Supply and Demand Dynamics09:48 Regulatory Challenges and Safety Concerns17:01 Research Background and Interest in Delta-8 THC19:33 Compliance and Regulation in Cannabis Sales21:50 Redesigning State and Federal Cannabis Policy24:24 The Future of Delta-8 THC Regulation27:39 Exploring Other Cannabinoids and Their Implications32:25 The Broader Landscape of Psychoactive Substances